General and clinical characteristics of patients and controls
| . | NDMM (n = 36) . | SMM (n = 11) . | MGUS (n = 24) . | Controls (n = 26) . |
|---|---|---|---|---|
| Age, median (range), y | 69 (38-90) | 73 (50-85) | 64 (42-89) | 60 (35-84) |
| Sex, male, n (%) | 20 (55) | 5 (45) | 7 (29) | 12 (46) |
| ISS stage,*n (%) | ||||
| ISS1 | 11 (34) | 3 (37.5) | NA | NA |
| ISS2 | 10 (32) | 3 (37.5) | NA | NA |
| ISS3 | 11 (36) | 2 (25) | NA | NA |
| Isotype, n (%) | ||||
| IgG | 21 (60) | NA | NA | NA |
| IgA | 8 (23) | NA | NA | NA |
| Light chain | 6 (17) | NA | NA | NA |
| Oligosecretory | 1 (3) | NA | NA | NA |
| Cytogenetics, n (%) | 33 (92) | NA | NA | NA |
| 17p deletion | 4 (12) | NA | NA | NA |
| −1p and/or +1q | 13 (40) | NA | NA | NA |
| FISH,†n (%) | 20 (55) | NA | NA | NA |
| t(4;14) | 2 (11) | NA | NA | NA |
| t(14;16) | 0 (0) | NA | NA | NA |
| LDH,‡median (range), U/L | 157 (89-407) | NA | NA | NA |
| Above normal, n (%) | 5 (18) | NA | NA | NA |
| . | NDMM (n = 36) . | SMM (n = 11) . | MGUS (n = 24) . | Controls (n = 26) . |
|---|---|---|---|---|
| Age, median (range), y | 69 (38-90) | 73 (50-85) | 64 (42-89) | 60 (35-84) |
| Sex, male, n (%) | 20 (55) | 5 (45) | 7 (29) | 12 (46) |
| ISS stage,*n (%) | ||||
| ISS1 | 11 (34) | 3 (37.5) | NA | NA |
| ISS2 | 10 (32) | 3 (37.5) | NA | NA |
| ISS3 | 11 (36) | 2 (25) | NA | NA |
| Isotype, n (%) | ||||
| IgG | 21 (60) | NA | NA | NA |
| IgA | 8 (23) | NA | NA | NA |
| Light chain | 6 (17) | NA | NA | NA |
| Oligosecretory | 1 (3) | NA | NA | NA |
| Cytogenetics, n (%) | 33 (92) | NA | NA | NA |
| 17p deletion | 4 (12) | NA | NA | NA |
| −1p and/or +1q | 13 (40) | NA | NA | NA |
| FISH,†n (%) | 20 (55) | NA | NA | NA |
| t(4;14) | 2 (11) | NA | NA | NA |
| t(14;16) | 0 (0) | NA | NA | NA |
| LDH,‡median (range), U/L | 157 (89-407) | NA | NA | NA |
| Above normal, n (%) | 5 (18) | NA | NA | NA |
FISH, fluorescence in situ hybridization; IgA, immunoglobulin A; IgG, immunoglobulin G; ISS, International Staging System; LDH, lactate dehydrogenase; NA, not available.
β2 microglobulin available for ISS grading in 32 out of 36 NDMM patients and 8 out of 11 SMM patients.
High-risk genetics by FISH, including del17p, t(4;14), and t(14;16), were tested in 20 out of 36 NDMM patients.
Available in 28 out of 36 NDMM patients.